Entries by TowerPR

Epigenetic markers – definition and significance for early cancer detection

As a biotechnology company, we have been researching cancer diagnostics on a molecular basis since 2012. We deal with epigenetic markers, which help us to recognise cancers, such as cervical cancer, in their preliminary stages. In this article, we explain the terms “epigenetics” and “epigenetic marker”. Epigenetics – what is it? Epigenetics deals with the […]

Pilot study: Cancer screening from home is possible

A large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much less frequent since the onset of the corona pandemic. A study by Hannover Medical School and the biotechnology company oncgnostics GmbH is testing self-tests as […]

Step USA – our virtual business trip

What has to be considered if you want to start as a German biotech company on the American market? What are the legal bases and challenges there? We got an insight at the “Step USA Virtual” from June 28th until July 1st, 2021. The four-day startup boot camp took place in New York and, due […]

Positive HPV test: What now?

Since the beginning of 2020, when early cervical cancer screening in Germany was supplemented by a routine HPV test for women over 35, more people have been confronted with a positive test result. First, it is important to mention: This is not a reason to panic. A positive HPV test result is not to be […]

We’ve moved: More space for new challenges

At the beginning of May, things were turbulent, because we moved into our new offices and laboratories. The new location in a business park in Jena enables us to create more opportunities for our company growth and to increase our (international) sales. It was the first time we’ve moved since the company was founded in […]

Study „OroCa-Graz“ – Study on Head-and-Neck tumors: oncgnostics GmbH cooperates with the Medical University of Graz

The biotechnology company oncgnostics GmbH is researching a method for diagnosing Head-and-Neck tumors together with the clinical department for general ENT at the Medical University of Graz as part of the “OroCa-Graz” study. 550,000 people worldwide develop carcinomas of this type every year. As only advanced stages of tumours are often diagnosed, more than 300,000 […]

International sales partnership with EUROIMMUN for Distribution of GynTect

Biotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN, a PerkinElmer company. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, Italy, Turkey and Poland. Also the test is expected to be approved and on sale in […]

PCR: Certainty in the shortest possible time

The method of the PCR stands for the polymerase chain reaction. The underlying process has fundamentally changed medical and biotechnological research. It is now considered the most important laboratory method for investigating the molecular structure of our genetic material (= DNA). This is partly due to the fact that the PCR analysis is versatile. It […]

Looking back on a successful year of research

2020 was a challenging year – also for our company. Nevertheless, we look back on successful achievements. GynTect® convinces in test comparison In November, the journal Clinical Epigenetics published a comparative study on cervical cancer diagnostics tests. Two tests based on epigenetic markers, oncgnostics’ GynTect® and QIAGEN’s QIAsure, were tested on a selection of patient […]